Rib-X Pharmaceuticals, Inc.' RX-04 Program Will be Featured at Windhover Information Inc.'s Therapeutic Area Partnerships Meeting as a "Top 10 Infectious Diseases Project to Watch"

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today that the Company’s RX-04 program has been selected by Windhover Information as one of the “Top 10 Infectious Diseases Projects to Watch.” RX-04 is Rib-X’s most advanced preclinical program focused on using a discrete, novel binding site within the bacterial ribosome to design and develop completely new classes of antibiotics to treat some of the most deadly and difficult-to-treat, multi-drug resistant Gram-positive and Gram-negative infections. Data recently presented at ICAAC 2012 demonstrated the unique activity of RX-04 compounds across a diverse array of bacterial pathogens including against carbapenem- and colistin-resistant strains of Klebsiella pneumoniae and major biodefense pathogens.